Navigation Links
OncoGenex increases economic interest in lead cancer drug OGX-011
Date:7/3/2008

conomic benefits from developing OGX-011 are all forward-looking statements. The potential risks and uncertainties include, among others, that clinical results will not be maintained in final data analysis, that current or future clinical trials will not be successful or confirm the results of earlier studies, that OncoGenex may not realize the anticipated economic benefits from developing OGX-011 on its own, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of OncoGenex. OncoGenex undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

CONTACT: OncoGenex Contact: Scott Cormack, President & CEO, (604) 630-5400, scormack@oncogenex.ca; OncoGenex Investor and Media Contact: Jason Spark, Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com


'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
7. Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. New Dual Cold Probe From Varian, Inc. Increases Sensitivity and Reduces Analysis Times for 13C NMR Experiments
10. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
11. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Colo. , Jan. 23, 2015  Array BioPharma Inc. ... has reached a definitive agreement with Novartis Pharma AG ... inhibitor currently in Phase 3 development.  This agreement is conditional ... GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 zFlo Motion ... pleased to announce an exciting product from a new partner. ... analysis solutions over the past 15 years, with offerings in ... recently, their 3D IMU system (inertial measurement unit), iSen, is ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... InterMune, Inc.,(Nasdaq: ITMN ) today announced that ... present at the BMO Capital Markets 2008 Focus,on Healthcare ... 10:00 a.m. EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... Bioheart, Inc.,(Nasdaq: BHRT ) a company ... monitor, diagnose and treat heart failure and,cardiovascular diseases, ... June 30, 2008., Recent Clinical Highlights:, ... the results of a preclinical,study involving the injection ...
... ... patients into screening completed in second LymphoStat-B(R), Phase 3 trial in systemic lupus erythematosus; completion of randomization ... expected in August 2008 -, - Initial data from Phase 2 ... third quarter 2008 ...
Cached Biology Technology:Bioheart, Inc. Announces Financial Results for Second Quarter 2008 2Bioheart, Inc. Announces Financial Results for Second Quarter 2008 3Bioheart, Inc. Announces Financial Results for Second Quarter 2008 4Bioheart, Inc. Announces Financial Results for Second Quarter 2008 5Bioheart, Inc. Announces Financial Results for Second Quarter 2008 6Bioheart, Inc. Announces Financial Results for Second Quarter 2008 7Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 2Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 3Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 4Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 5Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 6Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 7Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 8Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments 9
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014  23andMe, Inc., ... a study that pinpoints fine-scale differences in genetic ancestry of ... Since immigrants first arrived more than four hundred ... served as a meeting place for peoples from different continents. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... human world record for the most densely populated space and ... equivalent, the most species rich area on earth. The team,s ... reveal the record is contested between South America,s tropical rainforests ... of species in one space and the questions it raises ...
... he knows what was ailing Tiny Tim, the iconic character ... descriptions of both the symptoms and living conditions of 18th ... a combination of rickets and tuberculosis (TB). His findings ... of Pediatrics and Adolescent Medicine . Dr. ...
... a way to create temporary holes in the membranes of ... be published in JoVE, the Journal of Visualized Experiments ... for this method when we wanted to be able to ... on cells," said paper-author Dr. Delphine Dean. She said ...
Cached Biology News:European grasslands challenge rainforests as the most species-rich spaces on Earth 2Researchers print live cells with a standard inkjet printer 2
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... vitro diagnostic assays, all EIA/RIA plates are ... binding, high optical clarity and low background ... of the Certified Surface Chemistry Programme, which ... QA release specifications. Linkage: This CLS number ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: